Literature DB >> 20716233

Pharmacoeconomics: NICE's approach to decision-making.

Michael Rawlins1, David Barnett, Andrew Stevens.   

Abstract

Mesh：

Year:  2010        PMID： 20716233      PMCID： PMC2949905          DOI： 10.1111/j.1365-2125.2009.03589.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

2.  De Testimonio: on the evidence for decisions about the use of therapeutic interventions.

Authors:  Michael Rawlins
Journal:  Clin Med (Lond)       Date:  2008-12       Impact factor: 2.659
  2 in total
  38 in total

Review 1.  Crossing the fourth hurdle.

Authors:  Michael D Rawlins
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  From NCE to NICE: the role of pharmacoeconomics.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  The importance of being NICE.

Authors:  Annette Rid; Peter Littlejohns; James Wilson; Benedict Rumbold; Katharina Kieslich; Albert Weale
Journal:  J R Soc Med       Date:  2015-10-02       Impact factor: 5.344

4.  Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.

Authors:  Petra Baji; Manuel García-Goñi; László Gulácsi; Emmanouil Mentzakis; Francesco Paolucci
Journal:  Eur J Health Econ       Date:  2015-08-22

5.  Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.

Authors:  Ulrikke J V Hernæs; Kjell A Johansson; Trygve Ottersen; Ole F Norheim
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

6.  Expanded HTA, Legitimacy and Independence Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".

Authors:  Keith Syrett
Journal:  Int J Health Policy Manag       Date:  2016-09-01

7.  Operationalizing value-based pricing of medicines : a taxonomy of approaches.

Authors:  Jon Sussex; Adrian Towse; Nancy Devlin
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 8.  Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature.

Authors:  Kevin Marsh; Tereza Lanitis; David Neasham; Panagiotis Orfanos; Jaime Caro
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

9.  Monetary conversion factors for economic evaluations of substance use disorders.

Authors:  Kathryn McCollister; Xuan Yang; Bisma Sayed; Michael T French; Jared A Leff; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-07-18

10.  A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.

Authors:  Rajan Ragupathy; Katri Aaltonen; June Tordoff; Pauline Norris; David Reith
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.